Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
33
KALA Quote, Financials, Valuation and Earnings
Last price:
$0.75
Seasonality move
:
34.27%
Day range:
$0.76 - $0.86
52-week range:
$0.61 - $20.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.18x
P/B ratio:
8.34x
Volume:
2.3M
Avg. volume:
14.2M
1-year change:
-88%
Market cap:
$6.5M
Revenue:
--
EPS (TTM):
-$5.94
Analysts' Opinion
-
Consensus RatingKala Bio, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.50, Kala Bio, Inc. has an estimated upside of 90.82% from its current price of $0.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.79.
Fair Value
-
According to the consensus of 2 analysts, Kala Bio, Inc. has 90.82% upside to fair value with a price target of $1.50 per share.
KALA vs. S&P 500
-
Over the past 5 trading days, Kala Bio, Inc. has underperformed the S&P 500 by -28.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kala Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kala Bio, Inc. revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Kala Bio, Inc. reported revenues of --.
Earnings Growth
-
Kala Bio, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Kala Bio, Inc. reported earnings per share of -$1.07.
Enterprise value:
15.3M
EV / Invested capital:
0.72x
Price / LTM sales:
7.18x
EV / EBIT:
--
EV / Revenue:
7.72x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$332K
Return On Assets:
-81.87%
Net Income Margin (TTM):
--
Return On Equity:
-1375.54%
Return On Invested Capital:
-102.67%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$321K | -$260K | -$332K | -$63K | -$128K | |
| Operating Income | -$39M | -$40.3M | -$41.6M | -$9.6M | -$10.7M | |
| EBITDA | -$38.5M | -$40.1M | -$41.3M | -$9.5M | -$10.5M | |
| Diluted EPS | -$42.58 | -$12.47 | -$5.94 | -$1.93 | -$1.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $149.1M | $84.7M | $57.9M | $51.3M | $24.3M | |
| Total Assets | $193.8M | $85.7M | $61.1M | $54.1M | $25M | |
| Current Liabilities | $27.2M | $40.2M | $10.3M | $23.9M | $32.6M | |
| Total Liabilities | $132.3M | $86.7M | $49.9M | $47.2M | $33.7M | |
| Total Equity | $61.5M | -$968K | $11.2M | $6.9M | -$8.7M | |
| Total Debt | $105.2M | $42.6M | $35.8M | $36.7M | $29.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34M | -$32.5M | -$32M | -$4.7M | -$10.9M | |
| Cash From Investing | -$371K | -$146K | -$84K | -$90K | $1K | |
| Cash From Financing | $37.8M | $25.8M | $4M | -$180K | $30K | |
| Free Cash Flow | -$34.6M | -$32.6M | -$32.1M | -$4.8M | -$10.9M | |
KALA
Sector
Market Cap
$6.5M
$28.5M
Price % of 52-Week High
3.82%
51.82%
Dividend Yield
0%
0%
Shareholder Yield
17.82%
-1.4%
1-Year Price Total Return
-88%
-21.29%
Beta (5-Year)
-2.494
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.98
200-day SMA
Sell
Level
$5.47
Bollinger Bands (100)
Sell
Level
-0.02 - 12.22
Chaikin Money Flow
Sell
Level
-260.5M
20-day SMA
Sell
Level
$0.81
Relative Strength Index (RSI14)
Sell
Level
38.26
ADX Line
Buy
Level
36.38
Williams %R
Buy
Level
-86.2945
50-day SMA
Sell
Level
$0.99
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
461M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-17.8955)
Sell
CA Score
(Annual)
Level (-5.2158)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.9251)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Stock Forecast FAQ
In the current month, KALA has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The KALA average analyst price target in the past 3 months is $1.50.
-
Where Will Kala Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kala Bio, Inc. share price will rise to $1.50 per share over the next 12 months.
-
What Do Analysts Say About Kala Bio, Inc.?
Analysts are divided on their view about Kala Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kala Bio, Inc. is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Kala Bio, Inc.'s Price Target?
The price target for Kala Bio, Inc. over the next 1-year time period is forecast to be $1.50 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is KALA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kala Bio, Inc. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of KALA?
You can purchase shares of Kala Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kala Bio, Inc. shares.
-
What Is The Kala Bio, Inc. Share Price Today?
Kala Bio, Inc. was last trading at $0.75 per share. This represents the most recent stock quote for Kala Bio, Inc.. Yesterday, Kala Bio, Inc. closed at $0.79 per share.
-
How To Buy Kala Bio, Inc. Stock Online?
In order to purchase Kala Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KALA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KALA
Sector
P/E ratio
--
23.52x
PEG ratio
--
-0.01x
P/B ratio
8.34x
1.82x
Price / LTM sales
7.18x
1.60x
Growth Metrics
KALA
Sector
Revenue growth
--
4.8%
Earnings growth
44.47%
11.11%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$1.10
-$0.20
Profitability
KALA
Sector
Profitability FY 2024
-$259K
$3.5M
Return on invested capital
-102.67%
-31.16%
Return on assets
-81.87%
-27.72%
Return on equity
-1375.54%
-37.13%
Earnings Date
Last Earnings Date
May
13
Next Earnings Date
Dec
11
Estimated Next Earnings Date
Mar
12
Balance Sheet
KALA
Sector
Total cash
$21.1M
$27M
Short term investments
--
$25.7M
Total assets
$55.5M
$79.7M
Long term debt
$29.5M
$3.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
50
PLAB alert for Dec 10
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
